9ASD

VIR-7229 Fab fragment bound the SARS-CoV-2 BA.2.86 spike trimer (local refinement of the BA 2.86 RBD/VIR-7229 VHVL)

9ASD の概要

• エントリーDOI: 10.2210/pdb9asd/pdb
• EMDBエントリー: 43813
• 分子名称: VIR-7229 Fab heavy chain, VIR-7229 Fab light chain, Spike glycoprotein, ... (4 entities in total)
• 機能のキーワード: sarbecoviruses, spike glycoprotein, fusion protein, neutralizing antibodies, inhibitor, viral protein, structural genomics, seattle structural genomics center for infectious disease, ssgcid, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 167360.52

構造登録者

Park, Y.J.,Tortorici, M.A.,Seattle Structural Genomics Center for Infectious Disease (SSGCID),Veesler, D. (登録日: 2024-02-25, 公開日: 2024-10-16, 最終更新日: 2024-12-25)

主引用文献

Rosen, L.E.,Tortorici, M.A.,De Marco, A.,Pinto, D.,Foreman, W.B.,Taylor, A.L.,Park, Y.J.,Bohan, D.,Rietz, T.,Errico, J.M.,Hauser, K.,Dang, H.V.,Chartron, J.W.,Giurdanella, M.,Cusumano, G.,Saliba, C.,Zatta, F.,Sprouse, K.R.,Addetia, A.,Zepeda, S.K.,Brown, J.,Lee, J.,Dellota Jr., E.,Rajesh, A.,Noack, J.,Tao, Q.,DaCosta, Y.,Tsu, B.,Acosta, R.,Subramanian, S.,de Melo, G.D.,Kergoat, L.,Zhang, I.,Liu, Z.,Guarino, B.,Schmid, M.A.,Schnell, G.,Miller, J.L.,Lempp, F.A.,Czudnochowski, N.,Cameroni, E.,Whelan, S.P.J.,Bourhy, H.,Purcell, L.A.,Benigni, F.,di Iulio, J.,Pizzuto, M.S.,Lanzavecchia, A.,Telenti, A.,Snell, G.,Corti, D.,Veesler, D.,Starr, T.N.
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification.
Cell, 187:7196-, 2024

PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinity, receptor molecular mimicry, and interactions with RBM backbone atoms. Consequently, VIR-7229 features a high barrier for selection of escape mutants, which are rare and associated with reduced viral fitness, underscoring its potential to be resilient to future viral evolution. VIR-7229 is a strong candidate to become a next-generation medicine.

PubMed: 39383863
DOI: 10.1016/j.cell.2024.09.026

実験手法

ELECTRON MICROSCOPY (3.3 Å)